Improvements in our understanding of diabetes mellitus

Mayo Clinic Proceedings

Volumn 88, Issue 9, 2013, Pages 907-909

  Hirsch, Irl B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE MARKER; DISEASE SEVERITY; DYSLIPIDEMIA; EDITORIAL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; MORTALITY; OBESITY; PANCREAS ISLET BETA CELL; PHYSICAL ACTIVITY; PUBLIC HEALTH; SMOKING;

EID: 84884644073     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.07.011     Document Type: Editorial

References (19)

1. Loprinzi P, Ramulu PY. Objectively measured physical activity and inflammatory markers among US adults with diabetes: implications for attenuating disease progression. Mayo Clin Proc. 2013;88(9): 942-951.
2. Chase HP, Cooper S, Osberg I, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes. 2004;53(10): 2569-2573.
3. Das A, Mukhopadhyay S. The evil axis of obesity, inflammation, and type 2 diabetes. Endocr Metab Immune Disord Drug Targets. 2011;11(1): 23-31.
4. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008; 31(suppl 2):S161-S164.
5. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012;379(9833): 2243-2251.
6. Lascar N, Kennedy A, Jackson N, et al. Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD): a study protocol for a pilot randomized controlled trial. Trials. 2013;14:180.
7. Saur NM, Kongable GL, Holewinski S, O'Brien K, Nasraway SA. Software-guided insulin dosing decreases glycemic variability and hypoglycemia while controlling hyperglycemia in critically ill patients. Mayo Clin Proc. 2013;88(9): 920-929.
8. Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15(3): 344-351.
9. NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13): 1283-1297.
10. Hirsch IB. Understanding low sugar from NICE-SUGAR. N Engl J Med. 2012;367(12): 1150-1152.
11. Yang SH, Zhou YJ, Tian XF, et al; Beijing Heart and Metabolism Survey Study Group. Association of dysglycemia and all-cause mortality across the spectrum of coronary artery disease. Mayo Clin Proc. 2013;88(9): 930-941.
12. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355(9206): 773-778.
13. Korsiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111(23): 3078-3086.
14. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33(6): 1389-1394.
15. Zoungas S, Patel A, Chalmers J, et al; ADVANCE Collaborative Group. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15): 1410-1418.
16. Guden G, Barutta F, Chaturvedi N, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Diabetes Study. Diabetes Care. 2012; 35(7): 1598-1604.
17. Riddle MC, Ambrosius WT, Brillon DJ, et al; Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median of 3.4 year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care. 2010;33(5): 983-990.
18. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713): 481-489.
19. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6): 1364-1379.